drugset

drugset / Trial / NCT03517176

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

NCT03517176 ↗

Phase 1 Completed 30 enrolled Lisata Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Timeline

Start: 2018-07-31
Primary completion: 2020-06-19
Completion: 2020-06-19

Publications

Dean A, Gill S, McGregor M, Broadbridge V, Jarvelainen HA, Price T. Dual alphaV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterol Hepatol. 2022 Oct;7(10):943-951. doi: 10.1016/S2468-1253(22)00167-4. Epub 2022 Jul 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	certepetide	Peptide	—	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous

Indications